PDCD1 and hepatocellular carcinoma: Despite this, only a subset of HCC patients shows favorable responses to PD-1 and CTLA-4-based immunotherapies (10), underscoring the need for a deeper understanding of the cellular and molecular mechanisms underlying HCC pathogenesis, in particular the roles of hepatic immune cells.